Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

NCT04880434 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04880434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Lead sponsor
Kite, A Gilead Company
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2021
Completion date
June 17, 2025
Enrollment
95 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory mantle cell lymphoma